We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





NEXTGENPCR Endpoint Thermocycler Decreases PCR Amplification Time for SARS-CoV-2 to Eight Minutes

By LabMedica International staff writers
Posted on 06 Apr 2020
Molecular Biology Systems, B.V. More...
(Goes, The Netherlands), a biotechnology company, has developed a method using its NEXTGENPCR endpoint thermocycler and consumables that decreases PCR amplification time for SARS-CoV-2 to eight minutes. Combined with smaller reaction volumes, increased samples per run, and standard, affordable laboratory equipment, a qualitative protocol was generated that could readily detect SARS-CoV-2 control DNA, with equivalent sensitivity. A single unit, the size of a shoebox, could perform a hundred and eighty (180) amplification runs a day, an almost 10-fold increase over the current US Centers for Disease Control (CDC) recommended instrumentation. The detection of amplified product can be done with widely-available blue light gel document systems.

The NEXTGENPCR thermocycler uses patented heating and cooling technology to reduce PCR amplification cycles from hours to minutes. These technological advances are intended to support laboratorians across the life sciences market reduce costs and accelerate results. Since the NEXTGENPCR accepts both 96 and 384-well reaction plates, the company tested both versions to increase throughput. By utilizing 384-well plates, the machine successfully processed four times as many samples without a loss in performance. The 384-well reaction chambers only require 25% of the reaction volume which would lower the supply burden placed on laboratories following the current CDC protocol. The company is now collaborating with testing laboratories in the US and the Netherlands to transfer and validate the method.

“We sought to decrease what we identified as the longest step in the current testing scheme, amplification. We started with the CDC assay because it is well characterized and has been readily available,” said Gert de Vos, CEO and founder of Molecular Biology Systems. “This protocol produces a simple yes/no answer — so a single machine, is capable of running 24/7, with eight-minute runs may provide a scalable screening solution analyzing 22,860 samples per day.”

Related Links:
Molecular Biology Systems, B.V.


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Collection and Transport System
PurSafe Plus®
Sample Transportation System
Tempus1800 Necto
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: When assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a TCMR diagnosis (Photo courtesy of Thermo Fisher)

Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection

Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.